1-Deamino-8 D-arginine vasopressin decreases the production of 13-hydroxyoctadecadienoic acid by endothelial cells

Bioactive lipids as biomarkers of adverse reactions associated with apheresis platelet concentrate transfusion

Platelet concentrate (PC) transfusion seeks to provide haemostasis in patients presenting severe central thrombocytopenia or severe bleeding. PCs may induce adverse reactions (AR) that can occasionally be severe (SAR). PCs contain active biomolecules such as cytokines and lipid mediators. The processing and storage of PCs creates so-called structural and biochemical storage lesions that accumulate when blood products reach their shelf life. We sought to investigate lipid mediators as bioactive molecules of interest during storage and review associations with adverse reactions post-transfusion. To facilitate understanding, we focused on single donor apheresis (SDA) PCs with approximately 31.8% of PCs being delivered in our setting. Indeed, pooled PCs are the most widely transfused products, but the study of a single donor lipid mediator is easier to interpret. We are investigating key lipid mediators involved in AR. Adverse reactions were closely monitored in accordance with current national and regional haemovigilance protocols. Residual PCs were analysed post-transfusion in a series of observations, both with and without severe reactions in recipients. A decrease in the lysophosphatidylcholine species to produce the lysophosphatidic acid species has been observed during storage and in the case of AR. Lysophosphatidic acid increased with primarily platelet-inhibitor lipids. Anti-inflammatory platelet-induced inhibition lipids were weakly expressed in cases of severe adverse reactions. We therefore propose that a decrease in lysophosphatidylcholine and an increase in lysophosphatidic acid can prospectively predict serious adverse transfusion reactions.

[Systemic hemostatic drugs]

Understanding the haemostatic changes is crucial in developing strategies for the management of haemorrhage syndroma. In recent years, the revised model of coagulation ("cell based" model) provided a much more authentic description of the coagulation process. Pharmacological intervention, especially desmopresin, antifibrinolytics (synthetics and nature) and increasingly recombinant activated factor VII are being used in prevention and therapeutically to control bleeding of variety etiologies. Skillfull surgery combined with blood saving methods and careful management of blood coagulation will all help in sucessfull haemorrhage prevention and treatment, and reduce unnecessary blood loss and transfusion requirements and its attendant risks. Among the all avalaible tests, the use of thromboelastography has allowed for more detailed dynamic assessment of the various steps of hemostasis.

Sickle red blood cells stimulate endothelial cell production of eicosanoids and diacylglycerol

The effects of sickle red cell-endothelial cell interaction on endothelial cell arachidonic: acid (AA) mobilization, eicosanoid release, and diacylglycerol (DAG) production were evaluated by using bovine aortic endothelial cells. We have shown that coincubation of washed red blood cells (RBCs) from patients with sickle cell disease with endothelial cells stimulate AA release (90% increase as compared with buffer controls, n = 8, p < 0.002). Released AA was mobilized from membrane phosphatidylcholine and phosphatidylserine and was converted to eicosanoids via the cyclooxygenase and lipoxygenase pathways in increased amounts in the presence of sickle erythrocytes. The production of prostacyclin and 15-hydroxyeicosatetraenoic acid (15-HETE) were increased by 78% (p < 0.01) and 103% (p < 0.025), respectively, as shown by both chromatographic and immunoassay procedures. Sickle erythrocytes also stimulated the hydrolysis of endothelial cell phosphoinositides, including phosphatidylinositol-mono-phosphate (p < 0.03) and phosphatidylinositol-bis-phosphate (p < 0.006). This response was accompanied by a significant increase in the production of DAG (50% increase as compared with buffer control, n = 8, p < 0.025). In contrast, coincubation of washed erythrocytes from normal healthy donors with endothelial cells had no significant effect on endothelial cell phospholipid turnover. When the sickle RBC-induced biochemical changes in endothelial cells were contrasted with those observed with normal RBCs, the ability of sickle RBCs to induce AA mobilization and the production of mono-HETEs and DAG was markedly increased (p = 0.05 to p < 0.025). Because 15-HETE is a pro-adhesinogenic eicosanoid and DAG is an endogamous activator of protein kinase C, an enzyme involved in modulating cell surface adhesive properties, both 15-HETE and DAG could potentially play a role in the vascular pathophysiology of sickle cell disease.

von Willebrand disease in children and adolescents

The term von Willebrand disease includes many bleeding disorders caused by abnormalities of vWF. Frequent or severe bleeding may be indicative of vWD or other bleeding conditions. Primary care practitioners need to be familiar with vWD and evaluate possibly affected individuals with appropriate laboratory studies. Patients with vWD should be educated about their disorder and preventive measures to limit its effect. Medications are available that can treat or prevent bleeding complications for most patients with vWD. Intervention with blood products is occasionally necessary.

Desmopressin (DDAVP) acts on platelets to generate platelet microparticles and enhanced procoagulant activity

Desmopressin (DDAVP), an analog of vasopressin (AVP), has wide clinical application as an anti-hemorrhagic (AH) agent. DDAVP in vivo releases vWF from endothelial cells but is reported to have little action on platelets. However, DDAVP is often used to improve hemostasis in platelet dysfunctions. We examined the effect of DDAVP on platelet microparticle (PMP) formation and procoagulant activity in vitro using platelets from normal volunteers and in vivo in six patients receiving DDAVP therapy. In the former, platelets were incubated with DDAVP (0.5 to 25 nM) and PMP released were stained with FITC-labeled MAb alpha-GP IIb/IIIa for flow cytometry. Procoagulant activity was measured in a clot-based assay using Russel's viper venom (RVV) calibrated with cephalin. A mean increase of 2-3 fold was observed in both PMP and procoagulant activity. Parallel to these observations was a dose-dependent rise in organelle-associated Ca2+. The assays were also performed on six patients prior to and at one hour after infusion of DDAVP, and similar but lesser effects were observed. We conclude that DDAVP acts on platelets in vitro, and that these effects may contribute to the hemostatic action of DDAVP in platelet dysfunctions in vivo.